There’s a lot of buzz around healthcare stocks right now, particularly with Johnson & Johnson (JNJ), a name that has a longstanding reputation in the medical field. Recently, the company has been seeing positive shifts in terms of revenue and stock prices, suggesting they’re making strategic moves post-pandemic. JNJ’s stock has become more integrated, a process some refer to as “building a base.” The idea is that once a stock breaks out of a stable range, incredible movement can occur, especially if that range has been stable for a long time.
Currently, JNJ is in a significant transformation phase. They’ve decided to focus on two promising therapeutic areas: oncology and immunology, alongside their move into MedTech, which includes surgical robotics and cardiovascular devices. In 2023, they spun off their Consumer Products division, now known as Kenvue. This helps JNJ concentrate more on their high-growth drugs and free up necessary capital.
They’re also making strides in their pipeline with next-gen drugs like IMAAVY and Carvykti, and are heavily invested in advancing their robotics efforts, which could be pivotal for the future of medicine. Their recent expansion into the cardiovascular market, including alliances with companies like ShockWave and Abiomed, reflects a commitment to innovation. Moreover, their approach to mergers and acquisitions is evolving, with a focus on strategic, disciplined investments rather than just sweeping deals.
However, it’s not all smooth sailing. JNJ still faces legal challenges, particularly concerning litigation around talcum powder. They’ve tried multiple times to settle these issues but are now shifting strategies to handle cases individually. Interestingly, the market doesn’t seem overly concerned about how this will financially impact the company.
As of July 16th, JNJ was added to the Best Stock List, which coincides with an upbeat outlook for revenue. Over the past 30 years, their stock price has closely followed earnings trends, and recent movements have shown a sharp increase in earnings per share. JNJ also raised its guidance for the remainder of the year, boosting optimism among shareholders.
Across the healthcare sector, things have been rocky. The sector struggled but some stocks are experiencing a resurgence. Notably, companies like UNH and CNC have shown significant recent gains. In fact, the number of healthcare stocks on the positive list has grown from 11 to 17, highlighting some recovery.
JNJ, in particular, has been trading sideways since late 2022 but is now showing signs of a breakout. They expect 2025 revenue to reach $93.4 billion, marking consistent growth. Their recent guidance on earnings suggests a solid upward trajectory as well.
Investors are advised to keep an eye on JNJ, especially with a dividend yield hovering around 3%. If the stock dips under $150, it might be worth reconsidering their position. Short-term traders are looking for a breakout above $180, so a strategic approach toward investing during this period could pay off. As always, it’s essential to assess personal financial situations and consult with advisors if needed.
